Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Pharmaceuticals, Inc. : Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

05/04/2012 | 04:05pm US/Eastern

PARSIPPANY, N.J., May 4, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com. The webcast can also be accessed at the following URL: http://www.veracast.com/webcasts/baml/healthcare2012/id16635640.cfm

An archived version will be available approximately one hour after the live presentation ends and can be accessed at the same locations for 90 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology. Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the worlds established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

    CONTACTS:                         Investors:
                                      Lisa DeFrancesco
                                      (862) 261-7152

                                      Media:
                                      Charlie Mayr
                                      (862) 261-8030

(Photo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

SOURCE Watson Pharmaceuticals, Inc.

React to this article
Latest news on ACTAVIS INC
01/31 ACTAVIS : Malta Operations appoint new Managing Director
01/31 ALLERGAN : SEC Labels Actavis Registration Statement for Pending Acquisition of ..
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29 Valeant to buy Dendreon's prostate cancer vaccine Provenge
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
01/29 ACTAVIS : Malta Operations appoint new Managing Director
01/29 ACTAVIS : Entry into a Material Definitive Agreement, Other Events, Financial St..
01/29 ALLERGAN : SEC Labels Actavis Registration Statement for Pending Acquisition of ..
01/28 ACTAVIS : Richter and Actavis Announce Positive Phase III Results for Cariprazin..
01/28 ACTAVIS : to buy Auden Mckenzie for GBP306m
Dynamic quotes  
ON
| OFF